Genome Publications
https://doi.org/10.61096/ 978-81-981372-2-7_7

Chapter 7

Renal and Electrolyte Pharmacology: Therapeutic Strategies, Drug Dosing, and Emerging Innovations in Kidney Care

Miryala Roopa Rani
Principal, School of Pharmacy, Motherhood University, Roorkee, 247661

Markapudi Sucharitha
Assistant Professor, Department of Pharmacology,
Bomma Institute of Pharmacy, Allipuram, Telangana- 507318.

Abstract: Renal and electrolyte pharmacology encompasses a critical aspect of clinical therapeutics, particularly in patients with chronic kidney disease (CKD), acute kidney injury (AKI), and other renal dysfunctions. The kidneys play a pivotal role in drug elimination and homeostasis, and impairment in renal function profoundly alters pharmacokinetics and pharmacodynamics, necessitating careful dose adjustments and monitoring. This chapter provides a comprehensive overview of the pharmacological agents used in renal and electrolyte disorders, including diuretics, renoprotective agents, drugs for correcting electrolyte imbalances, and therapeutic strategies for managing anemia in CKD. It highlights the impact of dialysis on drug dosing, discusses nephrotoxic medications and mitigation strategies, and explores the influence of pharmacogenomics in personalizing treatment for renal patients. Moreover, novel therapeutic approaches, such as anti-fibrotic agents and endothelin receptor antagonists, are reviewed for their emerging roles in disease modification. The chapter concludes with regulatory perspectives from FDA and KDIGO on renal dose adjustments, emphasizing the integration of evidence-based dosing into clinical practice. With the rising prevalence of renal disorders worldwide, a detailed understanding of renal pharmacology is vital for optimizing drug therapy, preventing complications, and improving patient outcomes.

Keywords: Renal pharmacology, chronic kidney disease, diuretics, pharmacogenomics in nephrology

Citation: Miryala Roopa Rani, Markapudi sucharitha. Renal and Electrolyte Pharmacology: Therapeutic Strategies, Drug Dosing, and Emerging Innovations in Kidney Care. *Modern Therapeutic Pharmacology: Precision Therapeutics Across Organ Systems.* Genome Publications. 2025; Pp63-74. https://doi.org/10.61096/978-81-981372-2-7_7

7.0 INTRODUCTION

The kidneys serve as essential organs in maintaining internal homeostasis, particularly in the excretion of metabolic waste products and pharmacological agents. They play a central role in drug

elimination, especially for hydrophilic and low-molecular-weight compounds, primarily through glomerular filtration, tubular secretion, and reabsorption processes. These functions not only influence the plasma concentrations of medications but also determine the therapeutic efficacy and risk of toxicity, especially for drugs with narrow therapeutic indices [1].

Renal impairment significantly alters pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion. Among these, drug excretion is most profoundly affected. In chronic kidney disease (CKD), the reduced glomerular filtration rate (GFR) leads to the accumulation of renally eliminated drugs, necessitating careful dose modification. Furthermore, uremic toxins can displace drugs from protein-binding sites, increasing the free fraction of active drugs in plasma. Alterations in hepatic metabolism, changes in expression and function of drug transporters, and compromised renal tubular function further contribute to variability in drug handling in patients with renal dysfunction [2][3].

Beyond drug elimination, the kidneys are instrumental in regulating electrolyte and fluid balance, acid-base status, and endocrine functions such as erythropoietin production and vitamin D activation. This complex physiology is targeted by various drug classes used to treat renal and electrolyte disorders. Electrolyte disturbances, often observed in renal impairment, require precise pharmacologic intervention to restore homeostasis. Additionally, renally impaired patients often suffer from comorbidities such as hypertension, diabetes, and cardiovascular diseases, necessitating polypharmacy and heightened risk of drug–drug interactions and adverse drug events [4][5].

Given the increasing global prevalence of renal diseases and their complications, a comprehensive understanding of renal pharmacology has become imperative for clinicians and pharmacologists. This chapter aims to explore the pharmacological agents that influence renal function and electrolyte balance, including diuretics, renoprotective agents, drugs for managing electrolyte imbalances, and therapeutic strategies for anemia in CKD. Further, it covers essential aspects such as drug dosing in dialysis, nephrotoxicity prevention, pharmacogenomics, novel therapeutic advances, and regulatory guidelines for renal dose adjustments [6][7].

7.1 Diuretics: Classes and Mechanisms

Diuretics are a cornerstone in the pharmacological management of fluid overload, hypertension, heart failure, and certain renal conditions. These agents act by inhibiting specific transporters along various segments of the nephron, thereby promoting natriuresis and diuresis. Based on their site of action and mechanism, diuretics are classified into loop diuretics, thiazide diuretics, potassium-sparing diuretics, osmotic diuretics, and carbonic anhydrase inhibitors.

Loop diuretics such as furosemide, bumetanide, and torsemide act on the thick ascending limb of the loop of Henle, where they inhibit the Na^+-K^+-$2Cl^-$ co-transporter. These are the most potent diuretics and are used in managing pulmonary edema, congestive heart failure, and nephrotic syndrome. Loop diuretics increase excretion of calcium and magnesium, which can contribute to electrolyte imbalance if not closely monitored [8]. Thiazide diuretics like hydrochlorothiazide and chlorthalidone inhibit the Na^+-Cl^- symporter in the distal convoluted tubule, reducing sodium reabsorption. These are less potent than loop diuretics but are effective in treating hypertension and mild fluid retention. They reduce urinary calcium excretion, making them useful in preventing calcium stones [9].

Potassium-sparing diuretics, including amiloride, triamterene, and spironolactone, act on the late distal tubule and collecting ducts. While amiloride and triamterene directly inhibit epithelial

sodium channels (ENaC), spironolactone and eplerenone antagonize aldosterone receptors, reducing sodium reabsorption and potassium excretion. These agents are often used in combination with other diuretics to mitigate the risk of hypokalemia [10].

Each diuretic class has distinct pharmacodynamic profiles and side-effect patterns. For example, loop and thiazide diuretics can cause hypokalemia, metabolic alkalosis, and hyperuricemia, whereas potassium-sparing agents may lead to hyperkalemia, particularly in patients with renal impairment or those taking RAAS inhibitors [11]. Selection of the appropriate diuretic depends on the clinical indication, renal function, and desired electrolyte balance. Understanding their pharmacological distinctions is critical for tailoring therapy and avoiding adverse outcomes in renal and cardiovascular disorders [12].

7.2 Renoprotective Agents

Renoprotective agents aim to slow the progression of chronic kidney disease (CKD), especially in patients with diabetes and hypertension, by mitigating glomerular injury, reducing proteinuria, and preserving renal function. Among the most widely studied and clinically established renoprotective agents are angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), and sodium-glucose co-transporter 2 (SGLT2) inhibitors.

ACEIs, such as enalapril, lisinopril, and ramipril, inhibit the conversion of angiotensin I to angiotensin II, leading to vasodilation and decreased glomerular capillary pressure. This action reduces intraglomerular hypertension and proteinuria, two key contributors to CKD progression. ARBs like losartan, valsartan, and telmisartan block angiotensin II from binding to AT1 receptors, yielding similar renal and cardiovascular protective effects with improved tolerability in patients who experience ACEI-induced cough or angioedema [13]. Both drug classes have been shown to significantly delay the onset of end-stage renal disease (ESRD) and reduce the risk of cardiovascular events in high-risk populations [14].

Recent clinical trials have highlighted the nephroprotective role of SGLT2 inhibitors, including empagliflozin, canagliflozin, and dapagliflozin. These agents reduce glucose and sodium reabsorption in the proximal tubule, promoting natriuresis, reducing glomerular hyperfiltration, and improving metabolic parameters. Importantly, SGLT2 inhibitors exert benefits independent of glycemic control and have demonstrated significant reductions in the progression of CKD, hospitalization for heart failure, and cardiovascular mortality in both diabetic and non-diabetic CKD populations [15][16].

Additionally, non-steroidal mineralocorticoid receptor antagonists such as finerenone have emerged as novel renoprotective agents with anti-inflammatory and antifibrotic properties. The FIDELIO-DKD and FIGARO-DKD trials have shown that finerenone significantly reduces albuminuria and delays kidney function decline in patients with diabetic kidney disease [17].

Collectively, these renoprotective agents have reshaped the therapeutic landscape of CKD management. Their selection should be tailored based on patient comorbidities, baseline renal function, and potential for adverse effects such as hyperkalemia, hypotension, or acute kidney injury. Early initiation and careful monitoring of these therapies remain essential for optimizing renal outcomes and minimizing complications [18].

7.3 Drugs for Electrolyte Disturbances

Electrolyte imbalances are common complications in patients with kidney disorders, often requiring pharmacologic intervention. The kidneys play a central role in regulating sodium, potassium,

calcium, phosphate, and magnesium balance, and impaired renal function leads to significant disturbances in these electrolytes. Proper management is crucial to avoid neuromuscular dysfunction, arrhythmias, metabolic derangements, and bone disease.

Hyperkalemia is a frequent and potentially life-threatening condition in CKD, especially in patients on RAAS inhibitors or potassium-sparing diuretics. Initial treatment often includes intravenous calcium gluconate to stabilize cardiac membranes, followed by insulin with glucose to shift potassium intracellularly. Sodium bicarbonate may also be used in acidotic patients. For potassium elimination, loop diuretics and potassium binders like sodium polystyrene sulfonate, patiromer, or sodium zirconium cyclosilicate are used to remove excess potassium from the body [19][20].

Hyponatremia, defined as serum sodium levels below 135 mmol/L, results from water retention more commonly than sodium loss, especially in conditions such as heart failure, liver cirrhosis, or SIADH. Treatment involves fluid restriction for mild cases and administration of hypertonic saline for symptomatic or severe cases. Vasopressin receptor antagonists (vaptans), including tolvaptan and conivaptan, selectively block antidiuretic hormone receptors and promote aquaresis without significant sodium loss, proving useful in correcting euvolemic or hypervolemic hyponatremia [21].

Phosphate imbalances, especially hyperphosphatemia, are common in CKD due to reduced renal excretion. Elevated phosphate contributes to vascular calcification, secondary hyperparathyroidism, and bone disorders. Phosphate binders such as calcium carbonate, calcium acetate, lanthanum carbonate, sevelamer hydrochloride, and ferric citrate bind dietary phosphate in the gastrointestinal tract, preventing its absorption. Non-calcium-based binders are preferred in patients at risk of hypercalcemia or with extensive vascular calcification [22].

Hypocalcemia and hypermagnesemia also occur in advanced CKD. Hypocalcemia is usually secondary to hyperphosphatemia and reduced vitamin D activation; it is treated with calcium supplements and active vitamin D analogs like calcitriol or paricalcitol. Hypermagnesemia, although less common, is managed by reducing magnesium intake and enhancing elimination through loop diuretics or dialysis in severe cases [23].

In managing electrolyte disorders, it is essential to tailor therapy based on the underlying cause, severity, and concurrent conditions. Close monitoring of serum electrolytes, renal function, and cardiac status is vital to ensuring safe and effective treatment outcomes [24][25].

7.4 Anemia Management in CKD

Anemia is a common and debilitating complication of chronic kidney disease (CKD), particularly in patients with advanced stages. The primary etiology is a deficiency in erythropoietin (EPO), a hormone produced by the peritubular interstitial cells of the kidneys that stimulates erythropoiesis in the bone marrow. Additional contributing factors include iron deficiency, chronic inflammation, shortened red cell lifespan, and blood loss, especially in patients undergoing hemodialysis [26].

The cornerstone of anemia management in CKD involves the use of erythropoiesis-stimulating agents (ESAs), such as epoetin alfa, darbepoetin alfa, and methoxy polyethylene glycol-epoetin beta. These agents mimic endogenous EPO activity, stimulating red blood cell production. Their use has significantly reduced the need for blood transfusions in CKD patients. The target hemoglobin levels are typically maintained between 10 and 11.5 g/dL to avoid adverse cardiovascular outcomes

observed with overcorrection [27]. Dosing is individualized and adjusted based on hemoglobin response, iron status, and the presence of inflammation or infection.

Iron supplementation is essential to support effective erythropoiesis, as functional or absolute iron deficiency is common in CKD. Absolute deficiency is characterized by low ferritin and transferrin saturation (TSAT), whereas functional deficiency occurs when iron stores are adequate but not sufficiently mobilized due to inflammation. Iron can be administered orally or intravenously, with intravenous formulations (iron sucrose, ferric carboxymaltose, iron dextran) preferred in dialysis patients or those with poor oral tolerance [28].

The KDIGO (Kidney Disease: Improving Global Outcomes) guidelines recommend monitoring iron status using ferritin and TSAT before and during ESA therapy. The decision to initiate or continue ESAs depends on the availability of sufficient iron to support erythropoiesis. Emerging therapies, such as hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) like roxadustat and vadadustat, offer oral alternatives to ESAs and promote endogenous EPO production while improving iron metabolism [29].

Management of anemia in CKD requires a multidisciplinary approach with regular monitoring of hemoglobin, iron indices, and markers of inflammation. Patient-specific factors, including cardiovascular status, dialysis modality, and comorbidities, must guide therapy. Avoidance of excessive hemoglobin correction and appropriate iron repletion are critical to improving quality of life and reducing morbidity and mortality in this population [30][31].

7.5 Dialysis and Drug Dosing

Drug dosing in patients undergoing dialysis requires careful consideration due to altered pharmacokinetics, particularly in the elimination phase. Dialysis—whether hemodialysis (HD) or peritoneal dialysis (PD) can significantly impact drug clearance by removing drugs and their metabolites from circulation, necessitating dose adjustments to maintain therapeutic efficacy while avoiding toxicity [32].

Key pharmacokinetic parameters that determine dialyzability include molecular weight, protein binding, volume of distribution, and water solubility. Drugs with low molecular weight (<500 Da), low protein binding, small volume of distribution (<1 L/kg), and high water solubility are more readily removed by dialysis. For instance, aminoglycosides and vancomycin can be partially or extensively removed depending on the dialysis membrane used. High-flux dialysis membranes used in modern HD setups increase the clearance of many drugs, including some with previously negligible removal rates [33].

The dialyzability index classifies drugs based on the extent to which they are removed during dialysis. Highly dialyzable drugs often require supplemental dosing post-dialysis to maintain therapeutic plasma levels. For example, certain β-lactam antibiotics like cefepime or ceftazidime need post-dialysis dosing, while others like ceftriaxone, due to high protein binding and biliary excretion, may not [34].

In peritoneal dialysis, drug clearance is generally slower and less efficient compared to HD, necessitating different dosing regimens. Drugs administered intraperitoneally may have better local efficacy for peritonitis but require careful monitoring for systemic toxicity. Additionally, residual renal function plays a crucial role in drug clearance and should be considered alongside dialysis parameters when determining dosing frequency and amount [35].

Dose adjustments are generally guided by available pharmacokinetic data, dialysis-specific formularies, and institutional protocols. The FDA and other agencies recommend that clinical pharmacology sections of drug labels include specific dosing instructions for dialysis patients whenever possible. However, for many drugs, dosing recommendations are based on limited evidence, requiring clinicians to rely on clinical judgment, therapeutic drug monitoring (TDM), and published case studies [36].

Overall, individualized dosing in dialysis patients is critical for optimizing therapeutic outcomes and minimizing risks. Clinicians must assess dialysis modality, session duration, membrane type, and patient-specific factors such as fluid shifts and protein levels to tailor dosing appropriately [37][38].

7.6 Nephrotoxic Drugs and Risk Mitigation

Nephrotoxicity is a significant concern in clinical pharmacology, particularly in vulnerable populations such as patients with pre-existing renal impairment, the elderly, and those on polypharmacy regimens. Several classes of drugs can induce acute or chronic kidney injury through various mechanisms including direct tubular toxicity, altered glomerular hemodynamics, crystal nephropathy, and interstitial nephritis.

Aminoglycosides (e.g., gentamicin, amikacin, tobramycin) are among the most well-known nephrotoxic agents. These antibiotics accumulate in the renal cortex, particularly within proximal tubular epithelial cells, leading to mitochondrial dysfunction and oxidative stress. Nephrotoxicity is dose-dependent and associated with prolonged therapy and high trough concentrations. Strategies to reduce risk include extended-interval dosing, therapeutic drug monitoring (TDM), and avoidance of concomitant nephrotoxins [39].

Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, diclofenac, and naproxen impair renal prostaglandin synthesis, leading to decreased renal blood flow and potentially reversible acute kidney injury, especially in volume-depleted or heart failure patients. Chronic NSAID use may also result in papillary necrosis and chronic interstitial nephritis. Risk mitigation includes using the lowest effective dose, limiting duration, and avoiding use in high-risk patients [40].

Radiocontrast agents used in diagnostic imaging can induce contrast-induced nephropathy (CIN), a form of acute tubular necrosis. Risk is heightened in patients with diabetes, CKD, or volume depletion. Preventive strategies involve pre-procedural hydration with isotonic saline, minimizing contrast volume, using low-osmolality agents, and administering prophylactic agents such as N-acetylcysteine in high-risk cases, although evidence for some preventive therapies remains controversial [41].

Other notable nephrotoxic agents include amphotericin B, which induces tubular dysfunction and vasoconstriction; cisplatin, which causes oxidative stress and apoptosis in renal tubular cells; and tenofovir, known for proximal tubular injury leading to Fanconi syndrome. Awareness of drug-induced kidney injury patterns is essential for early recognition and intervention [42].

To mitigate nephrotoxicity risks, clinicians should:

- Identify patients at high risk based on renal function, comorbidities, and medication history.
- Adjust dosages according to renal function.
- Monitor renal parameters regularly, including serum creatinine, BUN, and urine output.
- Avoid unnecessary use of nephrotoxic drugs and implement alternative therapies when available.

- Educate patients about symptoms of renal dysfunction and encourage adherence to monitoring protocols [43][44].

A proactive approach to identifying nephrotoxic agents and implementing preventive strategies is essential for preserving renal function and improving patient safety in both acute and chronic care settings.

7.7 Pharmacogenomic Impact in Renal Disorders

Pharmacogenomics, the study of genetic variations that affect drug response, is increasingly recognized as a crucial factor in optimizing therapy for renal disorders. Genetic differences in drug-metabolizing enzymes, transporters, and receptors can significantly influence the pharmacokinetics and pharmacodynamics of medications used in patients with renal disease. Incorporating pharmacogenomic insights allows for more personalized, safe, and effective drug therapy, particularly in a population with altered renal clearance and heightened susceptibility to adverse effects.

One major pharmacogenomic determinant is the variability in cytochrome P450 (CYP450) enzymes. For example, polymorphisms in CYP3A5 influence the metabolism of calcineurin inhibitors like tacrolimus, commonly used in renal transplant patients. Individuals expressing CYP3A5*1 (expressors) require higher doses to achieve therapeutic levels, while non-expressors (CYP3A5*3/*3) metabolize the drug more slowly, increasing the risk of toxicity if doses are not appropriately adjusted [45]. Genotype-guided dosing of tacrolimus has been associated with improved outcomes in transplant recipients and is increasingly recommended in clinical guidelines.

Similarly, genetic variants in drug transporters such as ABCB1 (P-glycoprotein) and OATP1B1 affect drug distribution and excretion. ABCB1 polymorphisms have been linked to altered tissue levels of digoxin and other renally cleared drugs, potentially impacting therapeutic efficacy or toxicity. SLCO1B1 gene variants affect the hepatic uptake of statins, leading to increased plasma concentrations and a higher risk of statin-induced myopathy an important consideration in CKD patients who often require lipid-lowering therapy [46].

Pharmacogenomics also plays a role in predicting susceptibility to drug-induced nephrotoxicity. For example, patients with MT-RNR1 mutations are more prone to aminoglycoside-induced ototoxicity and nephrotoxicity, making genetic screening valuable prior to initiating such therapies in certain populations. Moreover, variations in genes encoding organic anion transporters (OATs) and multidrug and toxin extrusion proteins (MATEs) influence the renal handling of medications such as metformin and antivirals, affecting drug efficacy and adverse event profiles [47]. While the integration of pharmacogenomics into routine nephrology practice is still evolving, it holds promise for guiding dose individualization, selecting safer therapeutic alternatives, and minimizing adverse reactions. The development of point-of-care genotyping tools and incorporation of pharmacogenetic information into electronic health records (EHRs) are advancing the feasibility of precision medicine in nephrology [48].

Despite its potential, widespread implementation of pharmacogenomics in renal care faces challenges including cost, limited clinician awareness, and lack of universal guidelines for interpretation and actionability. Nonetheless, as evidence grows, particularly from large-scale genome-wide association studies (GWAS) and prospective trials, pharmacogenomics is poised to become a standard component in the personalized management of renal and electrolyte disorders [49][50].

7.8 Novel Therapies: Anti-fibrotics, Endothelin Receptor Antagonists

Recent advances in renal pharmacology have introduced novel therapeutic agents that target underlying pathophysiological mechanisms of chronic kidney disease (CKD), beyond traditional blood pressure and glycemic control. Among these, anti-fibrotic therapies and endothelin receptor antagonists (ERAs) are gaining attention for their disease-modifying potential, particularly in diabetic nephropathy and proteinuric CKD.

Renal fibrosis is the final common pathway leading to end-stage renal disease, characterized by extracellular matrix accumulation, tubular atrophy, and interstitial fibrosis. Anti-fibrotic agents aim to interrupt these processes by targeting key mediators such as transforming growth factor-beta (TGF-β), connective tissue growth factor (CTGF), and fibrogenic cytokines. Pirfenidone and bardoxolone methyl have demonstrated anti-inflammatory and anti-fibrotic properties in preclinical models. Bardoxolone, an Nrf2 activator, has shown promise in improving GFR in diabetic CKD patients in clinical trials, though concerns about cardiovascular safety have limited its broader adoption [51].

Endothelin-1 (ET-1) is a potent vasoconstrictor and pro-fibrotic peptide implicated in the pathogenesis of diabetic kidney disease. It exerts its effects via endothelin receptors A (ETA) and B (ETB), leading to glomerular hypertension, inflammation, and fibrosis. Selective ETA receptor antagonists, such as atrasentan and sparsentan, have emerged as potential renoprotective therapies. Atrasentan, in the SONAR trial, significantly reduced albuminuria and slowed kidney function decline in patients with type 2 diabetes and CKD when added to standard care, including RAAS inhibition [52].

Sparsentan, a dual endothelin type A and angiotensin II receptor antagonist, is currently under evaluation for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy. Early data suggest potent anti-proteinuric effects and favorable tolerability, with regulatory approvals anticipated for specific indications [53].

Additionally, other emerging therapeutic classes such as apelin receptor agonists, galectin-3 inhibitors, and microRNA-based therapies are being investigated for their potential to inhibit fibrosis, inflammation, and oxidative stress in progressive renal diseases. These agents represent a shift toward targeted and pathophysiology-driven treatment strategies.

The integration of novel agents into clinical practice requires comprehensive evaluation of their long-term safety, cost-effectiveness, and additive benefit over existing therapies. Nonetheless, their development marks a significant step forward in addressing the unmet needs in CKD management, particularly for patients who continue to progress despite optimized conventional therapy [54][55].

7.9 Regulatory Guidelines on Renal Dose Adjustments

Regulatory agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Kidney Disease: Improving Global Outcomes (KDIGO) provide structured recommendations for adjusting drug doses in patients with impaired renal function. These guidelines are vital for optimizing therapeutic outcomes and minimizing adverse drug reactions, which are significantly more common in patients with chronic kidney disease (CKD) due to altered pharmacokinetics and pharmacodynamics.

The **FDA** mandates that pharmaceutical companies evaluate the pharmacokinetics of drugs in individuals with varying degrees of renal impairment during the clinical development phase. The resulting data are incorporated into the drug's labeling, which often includes specific dosing recommendations based on estimated glomerular filtration rate (eGFR) or creatinine clearance (CrCl)

using formulas such as Cockcroft-Gault or MDRD. The FDA encourages the use of renal function stratification (mild, moderate, severe, end-stage renal disease) and often requires dedicated studies in dialysis patients [56].

KDIGO guidelines recommend careful evaluation of renal function using standardized equations and frequent monitoring in patients receiving nephrotoxic or renally cleared medications. KDIGO emphasizes individualized dosing, taking into account not only eGFR but also residual renal function, dialysis modality, comorbid conditions, and drug-specific pharmacokinetics. For example, in patients with CKD, dose adjustments are crucial for medications such as antibiotics (e.g., aminoglycosides, vancomycin), anticoagulants (e.g., low molecular weight heparins, DOACs), and antidiabetic agents (e.g., metformin, SGLT2 inhibitors) [57].

The EMA also requires assessment of renal function on drug disposition and recommends dosage adjustments be specified in the Summary of Product Characteristics (SmPC). Clinical decision support tools integrated within electronic prescribing systems are increasingly utilized to automatically alert clinicians about potential dosing issues based on real-time renal function data [58]. Dosing in dialysis patients presents an additional challenge. Guidelines highlight the importance of considering the dialyzability of each drug, the type of dialysis (high-flux vs low-flux hemodialysis, peritoneal dialysis), and session duration. Regulatory documents often include guidance on whether post-dialysis supplemental dosing is required, such as for drugs like aminoglycosides or certain cephalosporins [59].

Despite these guidelines, significant gaps remain, particularly for newer drugs or those with complex pharmacokinetics. The absence of robust data for certain populations, such as the elderly or those with fluctuating renal function, underscores the need for continued post-marketing surveillance and pharmacovigilance. Clinician education, access to updated formularies, and interdisciplinary collaboration with pharmacists are essential to ensuring safe and effective drug use in this high-risk population [60][61].

CONCLUSION

Renal and electrolyte pharmacology is essential for ensuring safe and effective drug therapy in patients with compromised kidney function. This chapter underscores the complex interplay between renal physiology and pharmacokinetics, necessitating precise drug selection and dosage adjustment in conditions like chronic kidney disease (CKD) and acute kidney injury (AKI). A wide array of pharmacologic classes such as diuretics, renoprotective agents, electrolyte modulators, and erythropoiesis-stimulating agents are vital for managing the multifaceted complications of renal disorders.

The impact of dialysis on drug clearance, risks posed by nephrotoxic medications, and advancements in pharmacogenomics are key considerations in personalizing renal care. Furthermore, novel therapeutic options like anti-fibrotic agents and endothelin receptor antagonists offer promising disease-modifying benefits in CKD. Adhering to regulatory guidelines from FDA and KDIGO for renal dose adjustments is crucial for preventing drug toxicity and enhancing outcomes.

In essence, renal pharmacology bridges clinical pharmacotherapeutics with evolving innovations and precision medicine. Clinicians must integrate a multidisciplinary, patient-centered approach to optimize drug therapy, reduce adverse events, and improve quality of life in individuals with renal and electrolyte disorders.

REFERENCES

1. Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther. 2008;83(6):898–903.
2. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075): 1238–1252.
3. Matzke GR, Aronoff GR, Atkinson AJ Jr, et al. Drug dosing consideration in patients with acute and chronic kidney disease a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80(11):1122–1137.
4. Meijers BKI, Evenepoel P, Anders HJ. Drug metabolism and kidney disease: the need for individualization. Kidney Int. 2019;95(2):258–267.
5. Stevens LA, Levey AS. Current status and future perspectives for CKD testing. Am J Kidney Dis. 2009;53(3 Suppl 3):S17–S26.
6. National Kidney Foundation. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266.
7. Golan DE, Tashjian AH, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Wolters Kluwer; 2017.
8. Ellison DH. Clinical pharmacology in diuretic use. Clin J Am Soc Nephrol. 2019;14(8):1248–1257.
9. Brater DC. Diuretic therapy. N Engl J Med. 1998;339(6):387–395.
10. Palmer BF, Clegg DJ. Electrolyte and acid–base disturbances in patients with diabetes mellitus. N Engl J Med. 2015;373(6):548–559.
11. Tamargo J, Ruilope LM. Pharmacologic differences of loop diuretics: implications for therapeutic use. Am J Cardiovasc Drugs. 2017;17(6):491–501.
12. Sica DA. Diuretic-related side effects: development and treatment. J Clin Hypertens (Greenwich). 2004;6(9):532–540.
13. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329(20):1456–1462.
14. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869.
15. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
16. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334.
17. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–2229.
18. McMurray JJV, Wheeler DC, Stefánsson BV, et al. Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease. Circulation. 2021;143(5):438–448.
19. Palmer BF. Regulation of potassium homeostasis. Clin J Am Soc Nephrol. 2015;10(6):1050–1060.
20. Fishbane S, Ford M, Fukagawa M, et al. A randomized trial of patiromer for hyperkalemia in patients receiving RAAS inhibitors. N Engl J Med. 2019;380(6):513–523.
21. Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(10 Suppl 1):S1–S42.

22. Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012;23(8):1407–1415.
23. Coyne DW. Iron indices: what do they really mean? Kidney Int Suppl. 2006;69:S4–S8.
24. Radhakrishnan J, Remuzzi G, Saran R, et al. Taming the chronic kidney disease epidemic: a global view of surveillance efforts. Kidney Int. 2014;86(2):246–250.
25. Delanaye P, El Nahas M. Anemia and chronic kidney disease: epidemiology, pathogenesis and management. Nephrol Ther. 2006;2(5):306–311.
26. Locatelli F, Bárány P, Covic A, et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant. 2013;28(6):1346–1359.
27. Macdougall IC, Ashenden M. Current and forthcoming erythropoiesis-stimulating agents, iron products and other novel anemia medications. Adv Chronic Kidney Dis. 2009;16(2):117–130.
28. Charytan C, Manllo-Karim R, Rao M, et al. Safety and efficacy of intravenous ferric carboxymaltose for treatment of iron deficiency anemia in patients with nondialysis-dependent chronic kidney disease: a randomized trial. Am J Kidney Dis. 2013;62(5):984–992.
29. Provenzano R, Besarab A, Sun CH, et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. J Am Soc Nephrol. 2016;27(12):411–420.
30. Singh AK, Coyne DW, Shapiro W, et al. Roxadustat treatment for anemia in chronic kidney disease. N Engl J Med. 2021;384(20):1921–1930.
31. Barraclough KA, Agar JWM. Dialysis dosing considerations: residual renal function and volume control. Nephrology (Carlton). 2016;21(3):216–218.
32. Nolin TD, Naud J, Leblond FA, Pichette V. Impact of renal failure on drug metabolism and transport. Clin Pharmacol Ther. 2008;83(6):898–903.
33. Aronoff GR, Berns JS, Brier ME, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. American College of Physicians; 2007.
34. Schaefer TJ, Wolford RW. Pharmacokinetics, altered. In: StatPearls. StatPearls Publishing; 2023.
35. Matzke GR, Frye RF. Drug administration in patients with renal insufficiency. In: Clinical Pharmacokinetics. 4th ed. McGraw-Hill; 2011.
36. FDA Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function—Study Design, Data Analysis, and Impact on Dosing and Labeling. U.S. Department of Health and Human Services, 2020.
37. Pirmohamed M. Drug toxicity in patients with kidney disease. Nat Rev Nephrol. 2010;6(3):157–165.
38. Perazella MA. Drug-induced acute kidney injury: diverse mechanisms of tubular injury. Curr Opin Crit Care. 2019;25(6):550–557.
39. Lopez-Novoa JM, Quiros Y, Vicente L, et al. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 2011;79(1):33–45.
40. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106(5B):13S–24S.
41. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006;100:S11–S15.
42. Perazella MA, Rosner MH. Drug-induced acute kidney injury. Clin J Am Soc Nephrol. 2019;14(11):1684–1696.

43. Pai AB, Boyce E, DeHart R. Drug dosing recommendations in chronic kidney disease: survey of prescriber knowledge. Int J Clin Pharm. 2013;35(3):400–407.
44. Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet. 2019;394(10212):1949–1964.
45. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623–653.
46. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011;63(1):157–181.
47. Izzedine H, Launay-Vacher V, Deray G. Pharmacogenetics of immunosuppressive drugs in renal transplantation. Kidney Int. 2005;67(1):445–455.
48. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–350.
49. Manolio TA, Fowler DM, Starita LM, et al. Bedside back to bench: building bridges between basic and clinical genomic research. Cell. 2017;169(1):6–12.
50. Roden DM, McLeod HL, Relling MV, et al. Pharmacogenomics. Lancet. 2019;394(10197):521–532.
51. de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013;369(26):2492–2503.
52. Heerspink HJL, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomized, placebo-controlled trial. Lancet. 2019;393(10184):1937–1947.
53. Appel GB, Radhakrishnan J, D'Agati V, et al. Sparsentan for the treatment of focal segmental glomerulosclerosis: a multicenter, randomized, double-blind, placebo-controlled trial. Kidney Int Rep. 2021;6(1):46–55.
54. Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884–894.
55. Mallipattu SK, He JC. The beneficial role of antifibrotic agents in kidney disease: update on current evidence and future perspectives. Adv Chronic Kidney Dis. 2017;24(2):110–117.
56. FDA. Clinical Pharmacology Guidance for Industry. U.S. Food & Drug Administration, 2020.
57. KDIGO. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1–150.
58. EMA. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function. European Medicines Agency, 2015.
59. Aronoff GR, Berns JS, Brier ME, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. American College of Physicians; 2007.
60. Patel UD, Balk EM, Loren D, et al. Systematic review: comparative effectiveness of strategies for monitoring renal function and dosing medications in patients with chronic kidney disease. Ann Intern Med. 2012;157(11):785–795.
61. Matzke GR, Aronoff GR, Atkinson AJ Jr, et al. Drug dosing consideration in patients with acute and chronic kidney disease a clinical update. Kidney Int. 2011;80(11):1122–1137.

1

Mrs. Miryala Roopa Rani
Principal, School of Pharmacy, Motherhood University, Roorkee,247661

2

Mrs. Markapudi sucharitha
Assistant professor, Department of Pharmacology, Bomma institute of Pharmacy, Allipuram, Telangana 507318.